Press Release 01.03.25
Devin demonstrates valuable leadership and legal expertise representing companies across various industries, and has earned the trust of his clients through his exemplary service in capital market transactions.
Devin Geng is a counsel in the firm’s corporate practice. Devin’s primary practice includes U.S. and Hong Kong capital market transactions, M&A and FCPA-related compliance matters.
Devin is also rapidly becoming a go-to lawyer in the biotechnology industry in China. His involvement in the industry began in 2018, when he was counsel for one of the first companies to be successfully listed under the HKEx’s Chapter 18A for pre-revenue biotechnology companies. Since then, Devin has represented numerous biotechnology companies for PE investments, capital market transactions and other transactions. He represented SinoMab, GenScript, ProBio and Mega Genomics, and other prominent biotechnology companies.
Representative Experience
- Advised SinoMab BioScience Limited in its global offering and IPO on the main board of the Hong Kong Stock Exchange. SinoMab BioScience is one of the earliest companies listed under Chapter 18A of the Hong Kong listing rules for pre-revenue biotechnology companies.
- Advised MultiMetaVerse in its $300 million de-SPAC transaction and subsequent listing on the NASDAQ. MultiMetaVerse is an animation, entertainment and mobile game company. The de-SPAC transaction took place at the height of domestic regulations on the gaming industry, and the transaction team was able to overcome significant hurdles to successfully close the transaction.
- Advised GenScript Biotech, a U.S-based biotechnology company focused on gene synthesis technology, and its indirect wholly-owned subsidiary Probio Technology in Probio Technology’s series financing since it establishment with prominent institutional investors and state funds.
View More
- Corporate
- Advised Big Tree Cloud International Group Limited, a company devoted to the development, production and sales of personal care products and other consumer goods in China, in its $500 million merger with special purpose acquisition company Plutonian Acquisition Corp., and subsequent listing on the NASDAQ.
- Advised Probio Technology in its Series C financing with investments from Legend Capital, Highlight Capital, Hillhouse Capital (Probio’s Series A investor) and other prominent institutional investors. Probio Technology raised approximately $224 million from the Series C investors.
- Advised MultiMetaVerse in its $300 million de-SPAC transaction and subsequent listing on the NASDAQ. MultiMetaVerse is an animation and entertainment company devoted to establishing an open community for its global users by providing high-quality entertainment experiences.
- Advised Mega Genomics Limited in its HK$215 million global offering and IPO on the main board of the Hong Kong Stock Exchange. Mega Genomics is the largest consumer genetic testing platform in China.
- Advised Probio Technology in its Series B financing transaction from Zhenjiang High-tech Venture Capital (HK) Limited, who subscribed minority equity interest in Probio Technology for $37.3 million. The transaction is executed concurrently with a real estate acquisition by Probio Technology from Zhenjiang High-tech Venture Capital.
- Advised De Well, an international logistics company, on the subscription of its equity interest by an investing vehicle of Cainiao, a global logistics service provider under Alibaba Group.
- Advised GenScript Biotech, a U.S.-based biotechnology company focused on gene synthesis technology, and its indirect wholly-owned subsidiary Probio Technology, in Probio Technology‘s Series A financing transaction from Hillhouse Capital, who subscribed minority equity interest in Probio Technology for $150 million, with a $125 million warrant to purchase additional shares.
- Advised SinoMab BioScience Limited in its global offering and IPO on the main board of the Hong Kong Stock Exchange. SinoMab BioScience is listed on the HKSE under Chapter 18A of the Hong Kong listing rules.
- Advised Fosun Tourism Group in its $428 million global offering and IPO on the Hong Kong Stock Exchange.
- Advised Mei Nian Investment and Meinian Onehealth as the issuer and parent guarantor, respectively, for Mei Nian Investment’s issuance of $200 million guaranteed senior notes due in 2021. Meinian Onehealth is one of the largest private health checkup service providers in China.
- Advised Liaoning Port Co., Ltd. for its HKEX disclosures regarding its merger by absorption with Yingkou Port Liability Co., Ltd.
- Advised a Chinese asset management company on its proposed U.S. initial public offering.
- Litigation/Dispute Resolution/Compliance
- Advised a large PRC investment fund in arbitration at the HKIAC for an acquisition and contractual dispute with the client receiving compensation and damages from arbitration.
- Advised a large Chinese state-owned enterprise on a contractual and intellectual property rights dispute against an American company, and successfully assisted the client in receiving compensation.
- Advised multiple global pharmaceutical companies, medical device companies and technology companies in conducting a series of compliance investigations and periodic compliance reviews for their business operations in China. Participated in subsequent negotiations with government agencies regarding the investigation and provided remediation recommendations regarding the client companies’ compliance policies.
Professional Highlights
- Member of the Shanghai Bar Association Specially-Invited Committee
- Guest Lecturer at Fudan Law School (2020 - Present)
Education
-
J.D., Emory University School of Law, 2014
B.A., University of Michigan, 2009
Admissions
-
New York
Languages
-
Chinese (Mandarin)
English